Date Mailed: ____ June 2009 Sheet 1 of 1

	FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 05822.0319USWO	Application Number: 10/521,038		
	IN AN APPLICATION	Applicant: ROOS et al.			
ı	(Use several sheets if necessary)	Filing Date: 31 October 2005	Group Art Unit: 1657		

			υ	S. PATENT DOCUMENT	rs			***************************************
EXAMINER INITIAL	DOCUM	ENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
					-		-	
					<u> </u>			
								~~~
			FOR	EIGN PATENT DOCUME	ENTS			
	DOCUMENT NO.		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		OTHER	DOCUMENTS	I (Including Author, Title, D	ate, Pertinent I	Pages, Etc.)		
		Horiuchi et al. "II. Progress in diagnosis of connective tissue disease and understanding of its clinical condition, 7. Complement." Ir. of the Japanese Society of Internal Medicine. Vol. 87. No. 12. 1998. pp. 2427-2433. (No Translation)						
		Fujita et al. "Recent Progress for molecular mechanism of protection against infection-Role complement-lectin pathway in protection against infection. Clinical Immunity. Vol. 35. No. 1. 2001. pp. 38-43. (No Translation)						
		Hockzema et al. "The Distortive Mechanism for the Activation of Complement Component CI Supported by Studies with a Monoclonal Antibody Against the "Arms" of Clq." Molecular Immunology. Vol. 25. No. 5. 1988. pp. 485-494.						
_		Collard et al. "Complement Activation after Oxidative Stress: Role of the Lectin Complement Pathway." Am. Jr. of Pathology. Vol. 156. No. 5. 2000. pp.1549-1556.						

23552 PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.